Seeking Alpha

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ...
Nasdaq

Larimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development Program

The company is hosting a conference call and webcast to provide regulatory updates on its clinical development program for nomlabofusp, indicating transparency and engagement with stakeholders. This ...
Seeking Alpha

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases Nomlabofusp was selected based on potential ...
The Business Journals

FDA selects Larimar Therapeutics for new program inspired by Operation Warp Speed

From the Philadelphia Business Journal. The Food and Drug Administration has selected a Montgomery County biotechnology company's lead drug candidate for a new program inspired by the federal agency's ...